Results 201 to 210 of about 45,032 (221)

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

European Journal of Cancer, 2014
Toshikazu Moriwaki, Mizutomo Azuma, Katsuhiko Higuchi   +2 more
exaly  

Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma

Drugs, 2017
Yvette N Lamb, Lamb Yvette N, Scott Lesley J   +2 more
exaly  

IRINOTECAN PREPARATION

2005
YOSHINO KEISUKE, NOZAWA SHIGENORI, ISOZAKI MASASHI, SAWADA SEIGO, KATO IKUO, MATSUZAKI TAKESHI   +5 more
openaire   +2 more sources

New approaches to prevent intestinal toxicity of irinotecan-based regimens

Cancer Treatment Reviews, 2004
Gianluigi Ferretti, Alain Gelibter, Andrea Alimonti   +2 more
exaly  

Irinotecan

Reactions Weekly, 2017
  +4 more sources

Importance of UDP-glucuronosyltransferase 1A1∗6 for irinotecan toxicities in Japanese cancer patients

Cancer Letters, 2008
Kimie Sai, Yoshiro Saito, Nahoko Kaniwa   +2 more
exaly  

Irinotecan

Reactions Weekly, 1999
openaire   +1 more source

Irinotecan

Reactions Weekly, 2015
openaire   +1 more source

Irinotecan and its active metabolite, SN‐38: review of bioanalytical methods and recent update from clinical pharmacology perspectives

Biomedical Chromatography, 2010
Nuggehally Srinivas
exaly  

Irinotecan

Reactions Weekly, 2018
openaire   +1 more source